Category: Metastatic Thyroid Cancer

Description

This page contains brief details about the drug trametinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Trametinib was approved by the U.S. Food and Drug Administration (FDA) in May 2013 for treating unresectable or metastatic melanoma.

Mechanism of Action of Trametinib

Trametinib is a medication called a mitogen-activated protein kinase (MAPK) kinase inhibitor. It inhibits the activity of the MEK enzyme, which is part of the MAPK pathway that is overactive in many cancer cells. In normal cells, the MAPK pathway plays an important role in regulating cell growth, differentiation, and survival. This pathway can become overactive and contribute to uncontrolled cell growth and tumour formation. It blocks the activity of the MEK enzyme, which is a key component of the MAPK pathway. Doing so helps slow down or stop the growth and spread of cancer cells with these specific genetic mutations. This can lead to a reduction in the size of tumours and an improvement in symptoms for patients with advanced or metastatic cancers.

Uses of Trametinib

Unresectable or metastatic melanoma

Non-small cell lung cancer in combination with Dabrafenib

Advanced or metastatic thyroid cancer

Metastatic solid tumours

Trametinib Dosage available

Trametinib is typically administered orally as a tablet or capsule taken by mouth. The dose and frequency of it will depend on the specific type of cancer being treated and the patient’s health status. For the treatment of melanoma, trametinib is usually taken once daily, either with or without food. It may be taken simultaneously as dabrafenib, another targeted therapy drug used in combination with trametinib for melanoma. In the management of non-small cell lung cancer, trametinib is usually taken once daily, at the same time as dabrafenib.